文献速递前列腺癌

微精蛋白β加入4Kscore预测高级别前列腺癌的前瞻性验证

Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
PubMed 文献 · BJU Int · 2020-12-28

这项国际多中心前瞻性研究纳入947例男性,评估基于四种激肽释放酶标志物的4Kscore模型预测活检Gleason分级组≥2前列腺癌的性能,并分析加入微精蛋白β(MSP)是否提升预测价值。结果显示4Kscore的AUC为0.824,加入MSP后判别力提升0.014-0.019,决策曲线分析显示4Kscore从7.5%阈值开始有临床净获益。

要点

  • 4Kscore预测活检GG≥2前列腺癌的AUC为0.824,优于基础模型和加入游离PSA的模型。
  • 在4Kscore模型中加入MSP可使判别力提升0.014-0.019。
  • 决策曲线分析显示4Kscore从7.5%阈值开始具有临床净获益。

核心结论

  • 基于四种激肽释放酶标志物的预定义4Kscore模型加入MSP后,可改善对活检GG≥2前列腺癌的预测判别力,并可用于辅助活检决策。

研究设计与样本

  • 前瞻性国际多中心研究,在三个学术医学中心共纳入984例男性,最终947例纳入分析。

主要发现

  • 947例最终分析人群中,273例(29%)活检为GG≥2前列腺癌。
  • 基础模型AUC为0.775,加入游离PSA后升至0.802,4Kscore模型为0.824。
  • 在4Kscore模型中加入MSP可使判别力提升0.014-0.019。
  • 决策曲线分析中,4Kscore从7.5%阈值开始显示临床净获益。

临床怎么用

  • 4Kscore可用于预测活检GG≥2前列腺癌并辅助活检决策,加入MSP可能进一步改善风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively evaluate the performance of a pre-specified statistical model based on four kallikrein markers in blood (total prostate-specific antigen [PSA], free PSA, intact PSA, and human kallikrein-related peptidase 2), commercially available as the 4Kscore, in predicting Gleason Grade Group (GG) ≥2 prostate cancer at biopsy in an international multicentre study at three academic medical centres, and whether microseminoprotein-β (MSP) adds predictive value. PATIENTS AND METHODS: A total of 984 men were prospectively enrolled at three academic centres. The primary outcome was GG ≥2 on prostate biopsy. Three pre-specified statistical models were used: a base model including PSA, age, digital rectal examination and prior negative biopsy; a model that added free PSA to the base model; and the 4Kscore. RESULTS: A total of 947 men were included in the final analysis and 273 (29%) had GG ≥2 on prostate biopsy. The base model area under the receiver operating characteristic curve of 0.775 increased to 0.802 with the addition of free PSA, and to 0.824 for the 4Kscore. Adding MSP to the 4Kscore model yielded an increase (0.014-0.019) in discrimination. In decision-curve analysis of clinical utility, the 4Kscore showed a benefit starting at a 7.5% threshold. CONCLUSION: A prospective multicentre evaluation of a pre-specified model based on four kallikrein markers (4Kscore) with the addition of MSP improves the predictive discrimination for GG ≥2 prostate cancer on biopsy and could be used to inform biopsy decision-making.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lonergan PE, Vertosick EA, Assel M, et al. Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. BJU Int. 2020. PMID: 33306251. doi:10.1111/bju.15320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。